Microfluidic-based prostate cancer model for investigating the secretion of prostate-specific antigen and microRNAs in vitro.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
19 07 2023
19 07 2023
Historique:
received:
28
04
2023
accepted:
16
07
2023
medline:
21
7
2023
pubmed:
20
7
2023
entrez:
19
7
2023
Statut:
epublish
Résumé
The study of prostate cancer in vitro relies on established cell lines that lack important physiological characteristics, such as proper polarization and expression of relevant biomarkers. Microphysiological systems (MPS) can replicate cancer microenvironments and lead to cellular phenotypic changes that better represent organ physiology in vitro. In this study, we developed an MPS model comprising conventional prostate cancer cells to evaluate their activity under dynamic culture conditions. Androgen-sensitive (LNCaP) and androgen-insensitive (PC3) cells were grown in conventional and 3D cultures, both static and dynamic. Cell morphology, the secretion of prostate-specific antigen, and the expression of key prostate markers and microRNAs were analyzed. LNCaP formed spheroids in 3D and MPS cultures, with morphological changes supported by the upregulation of cytokeratins and adhesion proteins. LNCaP also maintained a constant prostate-specific antigen secretion in MPS. PC3 cells did not develop complex structures in 3D and MPS cultures. PSA expression at the gene level was downregulated in LNCaP-MPS and considerably upregulated in PC3-MPS. MicroRNA expression was altered by the 3D static and dynamic culture, both intra- and extracellularly. MicroRNAs associated with prostate cancer progression were mostly upregulated in LNCaP-MPS. Overall dynamic cell culture substantially altered the morphology and expression of LNCaP cells, arguably augmenting their prostate cancer phenotype. This novel approach demonstrates that microRNA expression in prostate cancer cells is sensitive to external stimuli and that MPS can effectively promote important physiological changes in conventional prostate cancer models.
Identifiants
pubmed: 37468746
doi: 10.1038/s41598-023-38834-y
pii: 10.1038/s41598-023-38834-y
pmc: PMC10356943
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
MicroRNAs
0
Androgens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11623Informations de copyright
© 2023. The Author(s).
Références
Int J Clin Pract. 2011 Nov;65(11):1180-92
pubmed: 21995694
Biotechnol J. 2023 Jun;18(6):e2200434
pubmed: 36905340
Int J Mol Sci. 2020 Sep 16;21(18):
pubmed: 32948069
Front Bioeng Biotechnol. 2022 Nov 22;10:1057913
pubmed: 36483772
World J Oncol. 2020 Jun;11(3):79-87
pubmed: 32494314
Int J Mol Sci. 2022 Sep 12;23(18):
pubmed: 36142477
Lab Chip. 2021 Apr 20;21(8):1454-1474
pubmed: 33881130
Front Bioeng Biotechnol. 2022 Feb 10;10:840674
pubmed: 35223800
World J Urol. 2021 Oct;39(10):3789-3797
pubmed: 33990872
Biochim Biophys Acta Mol Cell Res. 2019 Aug;1866(8):1298-1309
pubmed: 30981892
BMC Cancer. 2016 Oct 11;16(1):789
pubmed: 27729023
RNA Biol. 2017 Dec 2;14(12):1791-1798
pubmed: 28820329
Biomicrofluidics. 2019 Nov 20;13(6):064116
pubmed: 31768202
Toxicol Sci. 2022 Jul 28;188(2):143-152
pubmed: 35689632
FEBS J. 2008 Nov;275(22):5703-13
pubmed: 18959755
ALTEX. 2022 Nov 03;40(3):408-424
pubmed: 36343109
Eur Urol. 2021 Oct;80(4):393-397
pubmed: 34074559
PLoS One. 2011 Feb 11;6(2):e16833
pubmed: 21347291
Br J Cancer. 2013 Apr 30;108(8):1668-76
pubmed: 23571738
In Vivo. 2016 09-10;30(5):573-9
pubmed: 27566074
J Cell Biochem. 2004 Oct 1;93(2):233-41
pubmed: 15368351
Cancers (Basel). 2022 Jan 27;14(3):
pubmed: 35158914
ALTEX. 2021 Nov 11;39(2):273–296
pubmed: 34766620
Pharmaceutics. 2021 Mar 13;13(3):
pubmed: 33805590
Invest New Drugs. 2001;19(4):283-91
pubmed: 11561687
Sci Rep. 2018 Mar 14;8(1):4530
pubmed: 29540740
Cancers (Basel). 2019 Dec 21;12(1):
pubmed: 31877738
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Cancer Res. 2004 Jun 1;64(11):3814-22
pubmed: 15172988
Br J Cancer. 2020 Dec;123(12):1767-1774
pubmed: 32901137
Tumour Biol. 2016 Aug;37(8):10435-46
pubmed: 26846108
Br J Cancer. 2014 Aug 26;111(5):955-64
pubmed: 24992580
Virchows Arch A Pathol Anat Histopathol. 1992;421(2):157-61
pubmed: 1381129
Adv Drug Deliv Rev. 2021 Aug;175:113798
pubmed: 34015419
Toxicol In Vitro. 2023 Sep;91:105624
pubmed: 37230229
Exp Biol Med (Maywood). 2017 Oct;242(16):1579-1585
pubmed: 28622731
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Appl Toxicol. 2021 Oct;41(10):1553-1567
pubmed: 33594739
Cancers (Basel). 2022 Aug 18;14(16):
pubmed: 36010983
Curr Opin Oncol. 2015 May;27(3):209-16
pubmed: 25689354
Drug Metab Pharmacokinet. 2018 Feb;33(1):49-54
pubmed: 29398302
J Cancer. 2020 Apr 7;11(14):4106-4114
pubmed: 32368293
Eur Urol. 2016 Aug;70(2):312-22
pubmed: 26806656
Int J Pharm. 2020 Nov 15;589:119788
pubmed: 32882369
Lab Chip. 2019 Sep 27;19(19):3152-3161
pubmed: 31469131
Springerplus. 2016 Jun 27;5(1):902
pubmed: 27386348